Butalia Sonia, Lee-Krueger Rachelle C W, McBrien Kerry A, Leung Alexander A C, Anderson Todd J, Quan Hude, Naugler Christopher, Chen Guanmin, Campbell David J T
Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
CJC Open. 2020 Jul 4;2(6):530-538. doi: 10.1016/j.cjco.2020.07.002. eCollection 2020 Nov.
Despite their proven efficacy to reduce cardiovascular disease, statin medication use remains low in individuals at high risk of cardiovascular disease considering their widespread availability and safety. Our objective was to explore the perspectives of patients and family physicians with regard to the barriers and facilitators of statin use in primary care.
In this qualitative descriptive study, we conducted 2 focus groups with patients (number, n = 8/6) and individual semistructured interviews with family physicians (n = 17) from community settings. Interviewers asked participants about barriers to and facilitators of statin use. Focus groups and interviews were digitally recorded, transcribed, and analyzed in duplicate using conventional content analysis.
Patients were averse to taking statins for a variety of reasons: medication avoidance and burden; inadequate buy-in for statin therapy; and difficulty remembering to take statins regularly. Family physicians perceived similar barriers and reported other barriers: lack of resources such as inadequate tracking systems; specialist-primary care provider guideline discordance; and lack of continuity and relationship. Patients expressed that key facilitators were patient education and support; splitting tablets to increase cost-effectiveness; and changing to a different statin or lower dose in those with side effects. Family physicians described several similar strategies to facilitate therapy as well as shared decision making and clinical decision support tools as enablers for improvement.
We identified several important barriers to and facilitators of statin use at the patient and prescriber level. This information offers insight into strategies to improve statin use and the development of innovative programs and interventions.
尽管他汀类药物在降低心血管疾病方面的疗效已得到证实,但考虑到其广泛可得性和安全性,在心血管疾病高危个体中,他汀类药物的使用仍然较少。我们的目的是探讨患者和家庭医生对于基层医疗中他汀类药物使用的障碍和促进因素的看法。
在这项定性描述性研究中,我们对患者进行了2次焦点小组讨论(每组人数分别为8名/6名),并对来自社区机构的家庭医生进行了个人半结构化访谈(n = 17)。访谈者询问参与者关于他汀类药物使用的障碍和促进因素。焦点小组讨论和访谈进行了数字录音、转录,并采用传统内容分析法进行了双人分析。
患者因多种原因不愿服用他汀类药物:避免用药和用药负担;对他汀类药物治疗的接受度不足;以及难以记住定期服用他汀类药物。家庭医生也认识到类似的障碍,并报告了其他障碍:缺乏资源,如跟踪系统不完善;专科医生与基层医疗服务提供者的指南不一致;以及缺乏连续性和医患关系。患者表示,关键的促进因素包括患者教育和支持;掰开药片以提高成本效益;以及对有副作用的患者换用不同的他汀类药物或降低剂量。家庭医生描述了几种类似的促进治疗的策略,以及将共同决策和临床决策支持工具作为改善的推动因素。
我们确定了患者和开处方者层面他汀类药物使用的几个重要障碍和促进因素。这些信息为改善他汀类药物使用的策略以及创新项目和干预措施的开发提供了见解。